

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT

OBTAINMENT OF THE DRUG REGISTRATION CERTIFICATE FOR LECANKITUG INJECTION (SUBCUTANEOUS INJECTION)

Recently, Livzon MABPharm Inc.*(珠海市麗珠單抗生物技術有限公司) (“**Livzon MAB**”), a controlling subsidiary of Livzon Pharmaceutical Group Inc.*(麗珠醫藥集團股份有限公司) (the “**Company**”), received the Drug Registration Certificate (Certificate No.: 2026S03179) approved and issued by the National Medical Products Administration of the People's Republic of China* (國家藥品監督管理局) (“**NMPA**”). The relevant particulars are announced as follows:

KEY PARTICULARS OF THE DRUG REGISTRATION CERTIFICATE

Generic Name: Lecankitug Injection (Subcutaneous Injection)

English/Latin name: Lecankitug Injection (Subcutaneous Injection)

Trade Name: 麗倍坦

Main Ingredient: Lecankitug

Dosage form: Injection

Specification: 160mg (1.6mL) / vial

Drug Registration Standard No.: YBS01072026

Application Matter: Drug registration (domestic manufacturing)

Registration Classification: Class 1 Therapeutic Biological Product

Shelf Life: 24 months

Marketing Authorization Holder: Livzon MABPharm Inc.

Manufacturer: Livzon MABPharm Inc.

National Drug Approval Number: 國藥准字 S20260065

Validity Period of Approval Number: 24 August 2031

Approval conclusion of the Acceptance Notice: Upon examination in accordance with the Drug Administration Law of the People's Republic of China and relevant provisions, the Product (as defined below) complies with the requirements for drug registration. Approval is granted for registration, and the Drug Registration Certificate is issued. The manufacturing process, quality standards, specifications and labels shall be implemented as attached.

DRUG DEVELOPMENT AND RELATED CONDITIONS

Lecankitug Injection (Subcutaneous Injection) (the “**Product**”) is jointly developed by Livzon MAB and Beijing Xinkanghe Biomedical Technology Co., Ltd.* (北京鑫康合生物醫藥科技有限公司) (“**Beijing Xinkanghe**”). It is a recombinant anti-human IL-17A/F humanized monoclonal antibody injection and the first independently developed innovative IL-17A/F dual-target biologic in China. It acts by simultaneously blocking the pro-inflammatory cytokines IL-17A and IL-17F, the indication for this registration application is: for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Psoriasis is a recurrent inflammatory skin disease triggered by a combination of genetic and environmental factors. There are approximately 125 million patients worldwide and over 7 million patients in China, of whom approximately 80% have plaque psoriasis.

The Product has completed a Phase III clinical trial in patients with moderate-to-severe plaque psoriasis, with Secukinumab as the active comparator. Data showed that the Product was superior to the control group in terms of speed of onset, skin clearance rate and long-term efficacy, with a safety profile comparable to that of the control group. The Product does not require an initial intensive induction phase and requires less frequent dosing than the comparator, which may enhance the patient experience and improve treatment adherence.

As at the date of this announcement, the cumulative direct investment in research and development expenses for the product amounts to approximately RMB223.31 million.

MARKET LANDSCAPE OF SIMILAR DRUGS

According to the databases of the NMPA and the Center for Drug Evaluation (“CDE”), as at the date of this announcement, with regard to IL-17A/F dual-target products, one imported product has been approved for marketing in China, and the Product is the first domestic IL-17A/F dual-target product approved for marketing in China. Regarding IL-17A and IL-17RA single-target products, three imported products and four domestic products have been approved for market launch in China.

According to IQVIA sampling statistical estimates, the domestic terminal sales value of IL-17A and IL-17RA single-target drugs in China in 2025 was approximately RMB2.976 billion.

IMPACT ON THE COMPANY AND RISK WARNING

After obtaining the Drug Registration Certificate, the Company can manufacture and market the Product. However, the operating performance of the Product is subject to uncertainties due to factors such as changes in the market environment. Investors are advised to exercise caution when making investment decisions and to pay attention to investment risks.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
27 August 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

** For identification purpose only*